Immix Biopharma Reports Third Quarter 2026 Financial Results and Update on Corporate Progress

On November 12, 2026 Immix Biopharma, Inc. ("Immix", the "Company", "we" or "us"), a global leader in AL amyloidosis, reported an update on corporate progress and financial results for the quarter ended September 30, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Recent NXC-201 Progress

– Positive clinical data: 89% complete response rate was reported across all 45 NEXICART-2 patients, with MRD-negativity indicating potential to reach up to 98% complete response rate in the future.
– Immix continues to advance its AL Amyloidosis launch readiness activities across commercial site activation, provider and payer engagement, manufacturing activities, and healthcare professional education.
Immix plans for its BLA submission in mid-2027, and NEXICART-3 front line trial initiation in the first half of 2027.

Interim NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at 68th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting

On Monday, December 14, 2026, NXC-201 NEXICART-2 interim clinical data will be presented at the 68th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting in New Orleans, LA.

Commercial Launch Preparation Continues with Strengthened Team

Immix has appointed David He, MD, PhD as Senior Vice President, Head of Technical Operations. Dr. He has contributed in a senior role to two approved BCMA CAR-Ts, CARVYKTI and FUCASO. Dr. He will lead chemistry, manufacturing, and controls at Immix, further accelerating the Company’s planned path to commercialization. Prior to Immix, Dr. He served as the Chief Technology Officer from pre-BLA to commercial-stage at IASO Biotherapeutics and as the Vice President, Technical Operations at Legend Biotech, as well as in a senior chemistry, manufacturing, and controls positions at Boehringer Ingelheim, and other senior roles.

Immix has appointed Karin McIntosh as Senior Vice President, Head of Regulatory Affairs. Karin has contributed to multiple FDA drug programs, including JANUVIA (FDA+EMA), EMFLAZA (FDA), ELZONRIS (FDA+EMA), and most recently, the approval of TREGZI (FDA, 2026). Karin will lead regulatory affairs at Immix in the United States and globally. Prior to Immix, Karin was Vice President, Head of Regulatory Affairs at Orca Bio and held senior regulatory positions at Stemline Therapeutics, PTC Therapeutics, Merck, and Pfizer.

Additionally, Immix has appointed additional key team members across its Commercial, Regulatory, Quality, Medical Affairs teams, and as Medical Science Liaisons.

Upcoming Events

– In addition to NEXICART-2 interim clinical data being presented at ASH (Free ASH Whitepaper) on Monday December 14, 2026, the Company will also present at the 45th Annual J.P. Morgan Healthcare Conference being held in San Francisco from January 11 – 14, 2027.
Financial Results for the Third Quarter Ended September 30, 2026

– Immix reported $340.9 million in cash, cash equivalents, and marketable securities as of September 30, 2026, which is expected to provide operating runway into mid-2028.
– Immix reported $15.9 million in operating expenses for the third quarter ended September 30, 2026.
About AL Amyloidosis
Amyloid light-chain (AL) amyloidosis is a devastating disease where the immune system, that’s supposed to protect, instead continuously produces toxic light chains that build up in organs including the heart, kidney, and liver, causing organ failure and death.

AL amyloidosis is the most common form of amyloidosis according to the National Institutes of Health. The number of patients in the U.S. with relapsed/refractory AL Amyloidosis is estimated to be growing at 12% per year according to Staron, et al Blood Cancer Journal, to approximately 30,506 patients in 2026.

The Amyloidosis market was $6.2 billion in 2025, and is expected to reach $6.6 billion in 2026, according to Grand View Research.

About NXC-201
NXC-201 is a sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy with a proprietary CD3ζ, CD8 hinge and binder "digital filter" designed to filter out non-specific activation. NXC-201 teaches the immune system to recognize and eliminate the source of the toxic light chains. NXC-201 has been awarded Breakthrough Therapy Designation (BTD) and Regenerative Medicine Advanced Therapy (RMAT) by the FDA, and Orphan Drug Designation (ODD) by the US FDA and in the EU by the EMA.

(Press release, Immix Biopharma, NOV 12, 2026, View Source [SID1234674674])

Vor Bio Expands Strategic Partnership with RemeGen, Adding Next Generation, Long-Acting RC298 to BAFF/APRIL Franchise

On November 12, 2026 Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, reported an amendment to its existing agreement with RemeGen Co., Ltd (HKEX: 9995, SHA: 688331) to add RC298, a next-generation dual BAFF/APRIL inhibitor, to Vor Bio’s exclusive license for development and commercialization outside of Greater China.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

RC298 is an engineered TACI-Fc fusion protein designed to inhibit both BAFF (B cell activating factor) and APRIL (a proliferation-inducing ligand), two key regulators of pathogenic B cell and plasma cell biology. RC298 was engineered to optimize functional potency, pharmacokinetics, and developability with a structural design intended to enable sustained dual pathway inhibition and extended dosing intervals. In preclinical studies, RC298 demonstrated potent inhibition of BAFF and APRIL compared to leading BAFF/APRIL inhibitors, as well as significantly prolonged systemic exposure, supporting its potential for a differentiated, best-in-class efficacy and dosing profile.

Building on telitacicept as the clinical foundation of Vor Bio’s BAFF/APRIL franchise with three ongoing registrational trials advancing across the myasthenia gravis spectrum and Sjögren’s disease, RC298’s differentiated long-acting profile has the potential to expand the franchise into additional autoimmune diseases and treatment settings, extending the therapeutic reach of dual BAFF/APRIL inhibition.

RC298 is currently in IND-enabling development, with an IND submission in China anticipated in the first half of 2027. RemeGen will continue to lead the preclinical and Phase 1 clinical development of RC298 in China, with both companies contributing to development efforts. Following completion of the Phase 1 clinical trial, Vor Bio will assume responsibility for subsequent clinical development, regulatory activities, and commercialization of RC298 outside of greater China.

"Over the past year, our successful execution has established Vor as a leader in the BAFF/APRIL field and RC298 meaningfully strengthens that position," said Jean-Paul Kress, M.D., Chairman and Chief Executive Officer of Vor Bio. "Our conviction in building this franchise is reinforced by what FcRn therapies have already demonstrated across multiple large autoimmune diseases. We believe BAFF/APRIL can build on that precedent by acting both upstream on B cells and downstream on plasma cells, with the potential for deeper, broader, and more durable disease control."

Dr. Kress continued, "Telitacicept remains our clinical foundation and near-term priority as we execute on our global Phase 3 programs in myasthenia gravis and Sjögren’s disease. RC298 is the next step in our broader campaign to create opportunities with a long-acting, next generation molecule across new diseases and treatment settings. We are building on a biology we know deeply, alongside a partner with extraordinary clinical and commercial experience in the pathway. With multiple differentiated ways to target BAFF and APRIL, we believe Vor is best positioned to build the leading franchise in this category and deploy each molecule where its profile can create the greatest advantage for patients."

"Telitacicept is the world’s first approved innovative therapy to target both BAFF and APRIL for the treatment of a range of B cell-mediated autoimmune diseases. It has been approved in China for five indications, and its global multicenter clinical trials are progressing well. The clinical evidence to date has demonstrated the potential benefits of dual BAFF/APRIL inhibition. RC298, our next generation, long-acting dual BAFF/APRIL inhibitor, has shown best-in-class potential," said Dr. Jianmin Fang, Chief Executive Officer of RemeGen. "This transaction will broaden both companies’ global autoimmune disease portfolios and accelerate the international development of RemeGen’s innovative pipeline. With RC298, we aim to bring an innovative treatment option to patients with autoimmune diseases worldwide while strengthening RemeGen’s brand and expanding its global presence."

Transaction Terms

Under the terms of the agreement, Vor Bio will provide RemeGen with approximately $56 million in aggregate upfront consideration, consisting of a $10 million upfront cash payment and pre-funded warrants to purchase 2.3 million shares of Vor Bio common stock with an exercise price of $0.0001 per share (representing an approximate value of $46 million based on Vor Bio’s closing share price on November 11). RemeGen will be eligible to receive up to an additional $300 million in development milestone payments, including $20 million payable upon the achievement of initial clinical development and technology transfer milestones. The existing collaboration’s sales milestone and royalty framework will continue to apply on an aggregated basis across all licensed products.

About Telitacicept

Telitacicept is a novel recombinant fusion protein designed to treat autoimmune diseases through dual inhibition of BAFF (also known as BlyS) and APRIL – two cytokines essential to B cell development and plasma cell survival. By inhibiting both pathways, telitacicept has the potential to reduce autoreactive B cells and autoantibody production, targeting key drivers of autoimmune pathology.

Telitacicept is approved in China for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), generalized myasthenia gravis (gMG), IgA nephropathy (IgAN), and Sjögren’s disease (SjD).

Vor Bio is advancing global development programs across major autoimmune indications, including a global Phase 3 trial in gMG and SjD, to support potential regulatory approvals in the United States, Europe, and Japan.

(Press release, Vor BioPharma, NOV 12, 2026, View Source [SID1234674690])

Racura Oncology Presents Bisantrene MYC Data at Frontiers in Cancer Science 2026 Conference

On November 12, 2026 Racura Oncology Limited (ASX: RAC), a late clinical-stage biopharmaceutical company developing new small molecule-based approaches to cancer treatment focused on silencing MYC gene expression, reported that new preclinical data on the MYC-directed mechanism of action of (E,E)-bisantrene are being presented as a poster at the Frontiers in Cancer Science (FCS) 2026 Conference, held in Singapore from 11–13 November 2026. The data show that (E,E)-bisantrene is the major active isomer (molecular form) of bisantrene able to stabilize the G-quadruplex in the MYC gene promoter region, leading to reduced MYC gene expression and MYC protein levels.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In these preclinical studies, light exposure converted (E,E)-bisantrene into less active isomers, which resulted in significantly less MYC G-quadruplex stabilization and a lowering of the inhibition of MYC gene expression.

In the study, exposing (E,E)-bisantrene to blue (440 nm) light reduced its content in solution to approximately 60% after 15 minutes, approximately 40% after one hour and an unquantifiable level after four hours. In MDA-MB-231 breast cancer cells, pure (E,E)-bisantrene suppressed MYC gene expression with a half-maximal effective concentration of 277 nM, compared with 514 nM to 1,166 nM for the light-exposed isomer mixtures, and reduced cancer cell viability with a half-maximal inhibitory concentration of 266 nM, compared with 310 nM to 825 nM for the mixtures. An isomer mixture containing 62% (E,E)-bisantrene stabilized the MYC G-quadruplex significantly less than pure (E,E)-bisantrene at the same concentration, and stabilization was restored when the amount of (E,E)-bisantrene was matched.

These findings build on the MYC gene expression inhibition data for (E,E)-bisantrene presented at the 2026 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting in April 2026 and further support the importance of the MYC-directed mechanism of action of RC220. Racura continues to investigate this mechanism through its ongoing research collaboration with Purdue University.

The poster is entitled "Light-Induced Isomerization Attenuates (E,E)-Bisantrene G-Quadruplex Binding and MYC Silencing" and reports work by Racura scientists and collaborators at the University of Wollongong, Australia.

Daniel Tillett, Ph.D., Chief Executive Officer of Racura Oncology, said: "These data show that (E,E)-bisantrene is the form that stabilizes G-quadruplex structures and inhibits MYC gene expression. Bisantrene can exist as several isomers, and confirming that the (E,E)-isomer is the active form supports our development of RC220 as a proprietary formulation of (E,E)-bisantrene. While these are preclinical findings, they add to the growing body of evidence for the MYC-directed mechanism of action of RC220."

Scientific Rationale

RC220 is being clinically developed to target non-canonical G-quadruplex DNA and RNA structures enriched in oncogenic regulatory regions, including promoters, untranslated regions and highly transcribed loci. Stabilization of these structures can disrupt transcriptional and post-transcriptional control networks that sustain malignant proliferation, including the silencing of MYC-driven growth and survival pathways.

(E,E)-bisantrene contains two hydrazone groups that can isomerize, and exposure to light converts it into (E,Z)- and, it is postulated, (Z,Z)-isomers. The FCS 2026 data indicate that the (E,E)-isomer is the form most responsible for MYC G-quadruplex stabilization, MYC suppression and anticancer activity, supporting Racura’s development of RC220 as a proprietary formulation of (E,E)-bisantrene.

About RC220 & (E,E)-bisantrene

RC220 is a proprietary formulation of (E,E)-bisantrene designed to overcome drug solubility issues that prevent safe peripheral intravenous infusion. (E,E)-bisantrene is a clinically validated small molecule anticancer agent that primarily functions via G4-DNA and RNA binding, leading to potent transcriptional silencing of the important cancer growth regulator MYC and downstream pathways.

(Press release, Racura Oncology, NOV 12, 2026, View Source [SID1234674709])

Fennec Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update

On November 12, 2026 Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, reported its financial results for the third quarter ended September 30, 2026 and provided a business update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Given the significant increase in demand that we are seeing quarter over quarter in 2026, we firmly believe in the sustainable growth potential of PEDMARK. We are driving this forward through strong commercial execution, investment in evidence generation to support its use, and operational enhancements that will continue to improve the overall patient and healthcare professional experience," said Jeff Hackman, chief executive officer of Fennec Pharmaceuticals. "Additionally, with net revenue, adjusted EBITDA, and our cash position reaching record highs this quarter, we will continue to be disciplined in our capital deployment as we move through the fourth quarter and look ahead to 2027."

Business Highlights:

Continued Commercial Momentum Within Key PEDMARK Accounts: The second full quarter following the significant expansion of our commercial organization contributed to another sequential quarter of demand growth, with total program enrollments up 23% and completed infusions up 58% over the second quarter of 2026. As the field team is now operating with greater reach and frequency to engage healthcare providers, Fennec expects that the productivity curve will continue to increase through the fourth quarter of 2026 and into 2027.

58th Annual International Society of Pediatric Oncology (SIOP) Annual Meeting: Detailed results from the investigator-initiated Phase 2 STS-J01 clinical trial evaluating PEDMARK for the reduction of cisplatin-induced ototoxicity in pediatric and adolescent and young adult (AYA) patients with non-metastatic solid tumors in Japan were featured in an oral presentation at SIOP 2026. These data demonstrated significant hearing protection and provide reassuring clinical context regarding antitumor activity with delayed PEDMARK administration. Full results from the study will be submitted for peer-reviewed publication.

Upcoming Events:

17th Annual Craig-Hallum Alpha Select Conference: The management team will host one-on-one investor meetings at the 17th Annual Craig-Hallum Alpha Select Conference, which will be held on Tuesday, November 17, 2026 at the Sheraton New York Times Square Hotel in New York City.

Piper Sandler 38th Annual Healthcare Conference: The management team will participate in a fireside chat on Thursday, December 3, 10:30 – 10:55 a.m. ET, at the conference and will host one-on-one investor meetings, which will be held at the Lotte New York Palace and will be available via webcast.

Financial Results for the Third Quarter Ended September 30, 2026:

Net Product Sales – For the third quarter of 2026, the Company recorded net product sales of approximately $19.4 million compared to $12.5 million in the third quarter of 2025. The increase in sales is attributable to growth across PEDMARK accounts including new accounts in the AYA population.

Selling and Marketing Expenses – The Company recorded $10.1 million in selling and marketing expenses in the third quarter of 2026 compared to $6.5 million in the third quarter of 2025. The increase is largely related to the higher costs associated with the commercialization and increased awareness initiatives of PEDMARK and related expenses to support the expansion of our sales organization.
General and Administrative (G&A) Expenses – The Company recorded $3.9 million in general and administrative expenses in the third quarter of 2026 compared to $5.4 million in the third quarter of 2025. The decrease in general and administrative expenses for the three-month comparable periods due to lower legal and professional fees as select litigation activities concluded.
Non-GAAP Adjusted EBITDA – The Company recorded $5.8 million in non-GAAP adjusted EBITDA in the third quarter of 2026 compared to non-GAAP adjusted EBITDA of $2.0 million for the same period in the prior year. A table reconciling non-GAAP measures is included in this press release for reference.

Cash Position – Cash and cash equivalents were $48.7 million as of September 30, 2026 compared to $41.2 million as of June 30 2026. We anticipate that our cash, cash equivalents and investment securities as of September 30, 2026, combined with the projected revenues from PEDMARK, will be sufficient to fund our business based on our current operating plan.

Third Quarter 2026 Conference Call Information

Date: Thursday, November 12, 2026
Time: 8:30 a.m. Eastern Time
Webcast Link: View Source
Participant Link: View Source

Financial Update

The selected financial data presented below is derived from our unaudited condensed consolidated financial statements, which were prepared in accordance with U.S. generally accepted accounting principles. The complete unaudited condensed consolidated financial statements for the period ended September 30, 2026, and management’s discussion and analysis of financial condition and results of operations will be available via www.sec.gov and www.sedar.com. All values are presented in thousands unless otherwise noted.

(Press release, Fennec Pharmaceuticals, NOV 12, 2026, View Source [SID1234674726])

IMUNON Reports Third Quarter 2026 Financial Results and Provides Business Update

On November 12, 2026 IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, reported financial results for the three months and nine months ended September 30, 2026, and highlighted recent business updates including progress in advancing Phase 3 clinical development of its lead candidate IMNN-001 in newly diagnosed advanced ovarian cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"IMUNON continues to make significant progress in the clinical development of IMNN-001 for advanced ovarian cancer," said Stacy R. Lindborg, Ph.D., President and Chief Executive Officer of IMUNON. "The data generated to date, our collaboration with the National Cancer Institute, and the favorable safety profile observed across studies support the ongoing advancement of the program and its potential to provide a transformative treatment for women with this difficult disease. We believe the OVATION 3 study is well positioned, with a broad patient population, two planned interim analyses, and a development strategy designed to support efficient execution and evaluation of the treatment’s potential benefit."

"We have also taken steps to continue to sharpen our strategic focus and strengthen IMUNON’s financial position. Through our agreement to transition ThermoDox to a dedicated development partner and our recent debt-for-equity exchange, we are demonstrating the disciplined approach to capital allocation that we believe is essential to advancing our most significant clinical opportunity while preserving opportunities for future value creation. As we look ahead, our priorities remain clear: execute OVATION 3, build on the growing body of evidence supporting IMNN-001 and advance a potentially transformative new treatment option for women who urgently need better outcomes."

RECENT DEVELOPMENTS

IMNN-001:

On July 23, 2026, the Company announced that translational and clinical data on IMNN-001 were presented at the inaugural AACR (Free AACR Whitepaper) Conference on Drug Discovery and Development (AACR D3), held July 21–24, 2026, in Boston. The presentation included findings from the randomized Phase 2 OVATION 2 study demonstrating that IMNN-001 was safe and well-tolerated, achieved local delivery of IL-12, and induced anti-tumoral immune responses, with no cytokine release syndrome or higher incidence of immune-related events observed in the experimental arm compared with control. Translational analyses indicated that IMNN-001 enhanced favorable ratios of CD8+ T cells to regulatory T cells and CD8+ to CD4+ cells in tumors and the tumor microenvironment, consistent with previously reported associations with improved outcomes. These findings support the ongoing pivotal Phase 3 OVATION 3 trial, which is designed to confirm the safety and survival benefit of IMNN-001 in frontline advanced ovarian cancer.

On September 10, 2026, the Company announced it had entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), part of the National Institutes of Health. Under the CRADA, the NCI’s Cancer Therapy Evaluation Program (CTEP), which will assume regulatory sponsorship, will support further clinical and non-clinical development of IMNN-001 under the NCI Experimental Therapeutics (NExT) Program. IMNN-001 is the first gene-based immunotherapy selected by NCI/CTEP for partnered clinical development under a CRADA.

On September 22, 2026, the Company announced that the Independent Data Monitoring Committee (IDMC) overseeing its ongoing Phase 2 minimal residual disease (MRD) translational study of IMNN-001 recommended that the study continue without modification, identifying no new safety signals and confirming comparable safety across both treatment arms.

On September 23, 2026, the Company hosted its 2026 R&D Day in New York, featuring presentations from the lead clinical investigators on the completed Phase 2 OVATION 2 study, the pivotal Phase 3 OVATION 3 study and the Phase 2 MRD study, together with translational data on how IMNN-001 remodels the tumor immune microenvironment. A replay is available on the Scientific Presentations page of the Company’s website, accessible through this webcast link.

On November 6, 2026, the Company announced new translational data from its randomized Phase 2 OVATION 2 study of IMNN-001 in newly diagnosed advanced ovarian cancer. The data are being presented in a poster at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 41st Annual Meeting (SITC 2026), being held November 4–8, 2026, at the Phoenix Convention Center in Phoenix, Arizona.

Corporate Development:

On September 29, 2026, the Company entered into an Exchange Agreement, under which $1.2 million of outstanding debt, together with accrued and unpaid interest, was exchanged for shares of the Company’s newly designated, non-convertible Series B Preferred Stock. The transaction reduces the outstanding balance of the Company’s A-1 Note by approximately 43% and increases stockholders’ equity while preserving financial flexibility, with no issuance of common stock or warrants.

On October 21, 2026, the Company announced that it had entered into an agreement to sell its rights to ThermoDox, a heat-activated liposomal formulation of doxorubicin, to VoxelDox Therapeutics, Inc. ("VoxelDox"). Under the agreement, closing of which is contingent on VoxelDox raising $2.5 million in funding, VoxelDox intends to advance the development of ThermoDox for the treatment of glioblastoma multiforme. In exchange, IMUNON will receive an equity ownership stake in VoxelDox, payments of up to $16.5 million contingent upon meeting development milestones and significant royalties on future net sales of ThermoDox product following commercial approval.

On October 27, 2026, the Company filed a registration statement on Form S-1 with the Securities and Exchange Commission relating to a proposed offering of its securities. The registration statement has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

FINANCIAL RESULTS FOR THE THIRD QUARTER 2026

Net loss available to common shareholders for the third quarter of 2026 was $3.8 million, or $0.64 per share, compared with a net loss of $3.4 million, or $1.16 per share, for the third quarter of 2025. Operating expenses were $3.4 million for the third quarter of 2026, largely unchanged from $3.5 million for the third quarter of 2025.

Research and development expenses were $1.8 million in the third quarter of 2026, compared with $1.9 million in the same period of 2025. Clinical costs associated with the OVATION studies were $0.4 million, compared with $0.5 million in the corresponding period in 2025. As enrollment in the OVATION 3 Study advanced, these costs were offset by lower manufacturing and clinical supply costs and lower other clinical and regulatory costs.

General and administrative expenses increased to $1.7 million in the third quarter of 2026, compared with $1.6 million in the same period of 2025, primarily reflecting higher outside professional fees.

FINANCIAL RESULTS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2026

Net loss available to common shareholders for the nine months ended September 30, 2026 was $10.9 million, or $2.01 per share, compared with a net loss of $10.3 million, or $5.53 per share, for the same period of 2025. Operating expenses were $10.5 million for the nine months ended September 30, 2026, compared with $10.4 million for the same period of 2025.

Research and development expenses increased to $5.6 million for the nine months ended September 30, 2026, compared with $5.3 million in the same period of 2025. Clinical costs associated with the OVATION studies of $0.8 million were flat with the comparable period in 2025, and manufacturing and clinical supply costs supporting the OVATION and MRD programs increased to $3.3 million from $3.0 million, partially offset by lower costs associated with the MRD Study and the closeout of the OVATION 2 Study.

General and administrative expenses were $5.0 million for the nine months ended September 30, 2026, largely unchanged from $5.1 million for the same period of 2025.

Net cash used in operating activities was $10.2 million for the nine months ended September 30, 2026, unchanged from the same period last year. At September 30, 2026, cash and cash equivalents were $4.0 million, and the Company held an additional $5.0 million of restricted cash.

Conference Call and Webcast

The Company will host a conference call to review third quarter 2026 financial results and provide a business update today, November 12, 2026, at 11:00 a.m. EST. To participate in the call, please dial (800) 715-9871 (U.S. and Canada/Toll Free) or (646) 307-1963 (U.S./Toll) and ask for the IMUNON Third Quarter 2026 Financial Results Call (Conference ID 4174261). A live webcast of the call will also be available here.

(Press release, IMUNON, NOV 12, 2026, View Source [SID1234674675])